Irbesartan Amarox (Irbesartan)

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and renal disease progression.

• Hypertension: lowers systolic and diastolic blood pressure in adults.
• Diabetic nephropathy: reduces the rate of decline in renal function in patients with type 2 diabetes.
• Proteinuric kidney disease: decreases urinary protein excretion and slows disease progression.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from inducing vasoconstriction and aldosterone release. This antagonism leads to relaxation of vascular smooth muscle, reduced peripheral resistance, and decreased sodium and water retention, thereby lowering blood pressure and mitigating renal damage associated with hyperfiltration.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Nausea: upset stomach with urge to vomit.
• Abdominal pain: discomfort in the stomach area.
• Back pain: soreness of the lower back.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or throat.
• Severe hyperkalaemia: dangerously high potassium levels.
• Acute renal failure: sudden loss of kidney function.
• Hepatic injury: abnormal liver enzyme elevations.
• Neutropenia: low white‑blood‑cell count increasing infection risk.
• Anaphylaxis: life‑threatening allergic reaction.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: check regularly to avoid hypotension.
• Renal function: evaluate serum creatinine and eGFR before and during treatment.
• Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with liver disease.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use can increase renal risk.
• Potassium‑sparing diuretics: may cause dangerous hyperkalaemia.
• ACE inhibitors: concurrent use raises angioedema risk.
• Lithium: can raise lithium concentrations, leading to toxicity.
• Strong CYP2C9 inhibitors (e.g., fluconazole): may elevate irbesartan levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• Loop or thiazide diuretics: additive blood‑pressure lowering.
• Other antihypertensives: may cause excessive hypotension.
• Rifampin: can reduce irbesartan plasma concentrations.
• High‑dose corticosteroids: may increase fluid retention, counteracting drug effect.